TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage enhancement of immune response to Fluvax vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Words-in-noise Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change From Baseline in Mucociliary Clearance (MCC) at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of photosensitivity reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rate of FVIII Inhibitor Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from AF and/or secondary left atrial arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and/or adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Bone Mineral Density (BMD) at Lumbar Spine (L1-L4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of interventions to achieve treatment success
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Muscle index (MI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Thyroid antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in blood oxygen level dependent (BOLD) contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: HANA incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Control of Nocturnal Hypoventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes in the visual discrimination task's perception threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of antimycobacterial drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in waist circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Pulmonary Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Diagnosis and staging of bronchial carcinoma and other conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: plasmatic EBV DNA change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of significant CAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SLUMS Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: App Acceptability by Patient Users
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: App Acceptability by Care Manager Users
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: App Usefulness by Patient Users
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: App Usefulness by Care Manager Users
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain measurement at lumbar area, hip and ankle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline The Beck Depression Inventory score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline General Anxiety Disorder-7 scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline DUKE-UNC-11 social support questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change from Baseline EuroQol quality of life questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Postprandial fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Wheal size of allergic skin reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Postoperative Fentanyl Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival (PFS) Rate at Month 36
Endpoint domain: Mortality/survival
Primary endpoint: Response of mood states
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Grade 3+ unusual CNS toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change From Baseline in A1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total post-surgical blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pharmacokinetic parameters for plasma thalidomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score GC (Global Confidence) of the MAPS scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of single doses of AdhAQP1
Endpoint domain: Adverse events/effects
Primary endpoint: Daytime Sleep Latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting plasma glucose and OGTT values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative refractive astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Packer Clinical Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toll-like Receptor 4 protein analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Toll-like Receptor 4 mRNA expression in bladder biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Toll-like Receptor 4 distribution and localization evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants with any treatment-emergent adverse event during the Treatment Period
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with any clinically significant clinical laboratory test value during the Treatment Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with any clinically significant electrocardiogram finding during the Treatment Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pharmacokinetic profile (PK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of bronchoscopic sampling methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total score of SHAPS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Tobacco Products Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Production of inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in Percent Volume of Lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Methylation levels in CpG islands of OPRM1 gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hormonal sensitivity to second line treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: self-care behaviour score
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change from pain scores until postoperative 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma antithrombin activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total Number of Emergency Department Visits Due to Asthma Attacks
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Completion of Diagnostic Peritineoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in baseline maternal glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of PSA response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Scale of Assessment of Negative Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite Outcome of Arterial Thromboembolic Events, Venous Thromboembolic Events and All-cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Total number of subjects with at least one TEAE
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Grade 3 Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Time to visualization of fluorescein on pCLE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ganglion cell layer thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bulk and color of infantile hemangioma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Guidance of antibiotic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Technical skills in performed surgical procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Subjective satiety responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral satiety responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pupillary light reflex parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Behavioral response
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: behavior performance (percentage of correct responses)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD signal of functional MRI scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Removal of oral plaque biofilm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of SCH 58235 and pitavastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-hours postprandial plasma glucose (PPPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of participants achieving blood pressure targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Blood Oxygen Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in regional cerebral oxygenation (rSO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anatomic Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Psychological Distress, Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Psychological Distress, Depression and Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Evidence of liver or muscle dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased liver fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with abnormal findings in electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's global assessment of pain control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Home Secondhand Smoke levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder Rate Based on UPDRS Items 32 and 33 at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Responder Rate Based on UPDRS Items 32 and 33 at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in UPDRS Total Score for Items 18 to 31 at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in UPDRS Total Score for Items 18 to 31 at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Late Lumen Loss (LLL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in LDL-c concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Menstrual Distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Health Related Quality of Life (HRQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in work productivity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Days without cold/flu symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: swallows
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: masticatory cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence/absence of the use of rescue treatment drugs
Endpoint domain: Adverse events/effects
Primary endpoint: Skin Characteristics changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety of Intramuscular administration of CD34-positive cells
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of Pelvic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of Pain during the relation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histomorphometric effects on bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Subjective Measures of Sleep Using Medical Outcomes Study -Sleep Scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Total Sleep Time Using a Sleep Diary
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in 100mm Pain VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Reported Experience outcomes (PREMS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Non-HDL Cholesterol (HDLC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percent of intraperitoneal carbon dioxide during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Very Good Partial Response (VGPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin Perfusion Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pathologic Complete Response Rate (pCRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Per Breast AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breath metabolite differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall 100-day mortality
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants who experience a serious adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: source of the index ADA
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: treatment modification
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: evolution of blood cortisol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Surgical method effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: percentage of patients with effective regional analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall disease survival
Endpoint domain: Mortality/survival
Primary endpoint: Difference in AUCs between diagnostic methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment Related Adverse Events (TRAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in inattention and hyperactivity/impulsivity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of surviving infants without CLD
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients with abnormal changes from baseline in tympanometry
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Composite Responders of at Least 2-Level Improvement of Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Clinical Benefit Response (CBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pulmonary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: postoperative pain conditions
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative probability of pregnancy for six months of typical use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cumulative probability of pregnancy for six cycles of consistent use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cumulative probability of study discontinuation through six months of CS gel use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: percent change in plasma LDL-C concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Pain Killer Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to return to full physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Flap necrosis
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12 Endpoint (5 mg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score at Week 12 Endpoint (5 mg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12 Endpoint (2.5 mg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score at Week 12 Endpoint (2.5 mg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional Distribution of Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of subjects with normal serum sodium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Offspring adiposity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Offspring neurocognitive and behavioural development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total Score on the Patient Health Questionnaire 9-Item (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Degree of adherence to clinical practice guidelines
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Depth of demarcation line
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time duration to stop bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Alveolar-arterial oxygen partial pressure difference (AaDO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Verbal Fluency Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Survival post transplant
Endpoint domain: Mortality/survival
Primary endpoint: unsuspected death
Endpoint domain: Mortality/survival
Primary endpoint: anaphylactic shock
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of Udenafil and Dapoxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of Udenafil and Dapoxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure of syphilis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants Who Completed a 4-dose Series of Catumaxomab Infusions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Dosage of analgesic opioid agent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive-psychosocial functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Symptom free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes